The present invention relates to intraventricular placement of a ventricular assist device, to components useful in such devices, and to methods of using the same.
In certain disease states, the heart lacks sufficient pumping capacity to meet the needs of the body. This inadequacy can be alleviated by providing a mechanical pumping device referred to as a ventricular assist device (“VAD”) to supplement the pumping action of the heart. Considerable effort has been devoted to providing a VAD which can be implanted and which can remain in operation for months or years to keep the patient alive while the heart heals, or which can remain in operation permanently or until a suitable donor heart becomes available if the heart does not heal.
The VAD is typically connected to the heart, most commonly to the left ventricle. For example, a VAD may include a pump which is installed in the body outside of the heart. The VAD may have an inlet cannula connected to the interior of the left ventricle and connected to the intake of the pump. The VAD may also include an outlet tube connected between the outlet of the pump and the aorta. Once connected, the VAD and the heart both pump blood from the left ventricle to the aorta.
As described, for example, in the U.S. Pat. Nos. 5,376,114 and 6,217,541 certain VADs having pumps are arranged so that at least a portion of the pump is disposed within the heart when the VAD is implanted within the patent. These VADs incorporate pumps which are connected to separate electric motors by enlongated driveshafts. Such shaft-driven pumps suffer from significant drawbacks. Commonly assigned, copending U.S. patent application Ser. No. 12/072,471, the disclosure of which is hereby incorporated by reference herein, discloses the VAD having a unitary pump and motor adapted for positioning within the arterial system as, for example, within the aorta.
Despite the considerable effort devoted to improvements in VADs, still further improvement would be desirable.
The words “proximal” and “distal” are used herein to denote directions and ends of the device and components. As used herein, when referring the ventricular assist device or components, the term “proximal” refers to the direction toward the surgeon or other operating room personnel during installation of the device and the term “distal” has the opposite meaning.
One aspect of the present invention provides a ventricular assist device for intraventricular placement inside a heart of a mammalian subject. The device preferably includes an anchor element such as a ring configured to be mounted adjacent an apex of the subject's heart, and also desirably includes an elongate member having proximal and distal ends. The device according to this aspect of the invention desirably also includes a pump having a housing, an inlet and an outlet a rotor within the housing and electric drive coils carried on the housing for magnetically driving the rotor. Preferably, when the device is implanted in the heart, the anchor element and the pump are fixed to the rigid elongate member remote from one another so that the rigid elongate member maintains the pump in position relative to the anchor element and hence with respect to the heart.
In certain embodiments of the device according to this aspect of the invention, the pump may have an axis extending between the inlet and outlet and the rigid elongate member may have an axis offset from an axis of the pump housing. Preferably, the elongate member extends substantially parallel to the axis of the pump.
The elongate member may include a bore extending in the proximal and distal directions thereof, the device further comprising wiring extending through the bore to the pump. The device may further include a tubular outflow cannula defining a bore, the bore having an inlet at a proximal end thereof connected to the outlet of the pump. The outflow cannula preferably includes a tip at the distal end thereof, the tip having at least one opening and desirably having a plurality of openings. Preferably, the tip of the outflow cannula projects through an aortic valve but terminates short of the arch of the aorta.
Another aspect of the present invention provides a ventricular assist device for intraventricular placement inside a heart of a mammalian subject. The device preferably includes an anchor element such as a ring configured to be mounted adjacent an apex of the subject's heart, and also desirably includes an elongate member having proximal and distal ends. The device according to this aspect of the invention desirably also includes a pump having a housing, an outflow cannula preferably having a tip at the distal end thereof. Preferably, the tip of the outflow cannula projects through an aortic valve but terminates short of the arch of the aorta. The ring and the pump are connected to the rigid elongate member remote from another so that the rigid elongate member maintains the pump in position relative to the anchor element.
A further aspect of the present invention provides a method of installing a ventricular assist device in a mammalian subject. The method according to this aspect of the invention desirably comprises mounting a pump to the subject so that an inlet of the pump communicates with the left ventricle of the heart, and positioning an outflow cannula of the pump so that the outflow cannula extends from within the left ventricle through the aortic valve but terminates short of the arch of the aorta.
Yet another aspect of the present invention provides additional methods of placing a ventricular assist device at a location inside a heart of a mammalian subject. The method according to this aspect of the invention desirably comprises providing an anchor element such as a ring and a pump to an elongate member remote from one another so that the elongate member maintains the pump in position relative to the anchor element, advancing the pump through an opening in an apex of the subject's heart and into an intraventricular region of the subject's heart, and mounting the anchor element to an apex of the subject's heart. Preferably, the pump further comprises a tubular outflow cannula, and the pump and cannula are positioned by the anchor element and elongate member so that the tip of the outflow cannula projects through the aortic valve but terminates short of an arch of the aorta.
Referring to the drawings, wherein like reference numerals refer to like elements, there is shown in
Pump 20 is shown in
A motor stator 24 is disposed around the outside of tubular housing 22. The motor stator is arranged to provide a rotating magnetic field. Preferably, stator 24 contains both magnetic laminations and wire coils (not shown). Sequencing the electrical current through the wire coils produces the rotating electromagnetic field necessary. Stator 24 can be a conventional slotted or slotless design or may utilize a toroidal design.
A rotor 26 is disposed within bore 29 shown in
The features of the rotor and stator may be generally as shown in the aforementioned copending, commonly assigned U.S. patent application Ser. No. 12/072,471. However, the pump of this embodiment typically is larger than a pump intended for positioning within an artery. For example, the pump used in this embodiment may be about 21 mm outside diameter and about 34 mm long, and may have a rotor about 10 mm in outside diameter. The pump desirably is arranged to deliver about 4 to 6 L/min flow rate against a pressure head of about 100 mm Hg. As an alternative to the unitary magnetic rotor discussed above, a conventional rotor design involving placement of magnets sealed within a rotor formed from non-magnetic material may be used.
The pump also includes diffuser blades 28 are mounted within housing 22 downstream from rotor 26, between the rotor and the outlet 23. As best seen in
Pump 20 has an exterior shroud surrounding the housing 22 and motor stator 24. The shroud may be formed from a biocompatible metal such as titanium, a ceramic, or a biocompatible polymer. Exterior thromboresistant coatings may also be utilized to improve hemocompatibility. The shroud defines a first attachment portion 30 at the proximal end of the housing, near inlet 21. The first attachment portion 30 (
The apparatus also includes an elongate member 60 which has a proximal end 61, a distal end 63 and a bore 62 therethrough. Preferably, elongate member 60 has an axis along its direction of elongation which axis is parallel to the axis 19 of the pump body but offset from axis 19 in a direction transverse to both axes. Merely by way of example, elongate member 60 may be a tube formed from titanium or other biocompatible metal. Member 60 desirably is substantially rigid. That is, the member desirably is rigid enough to maintain the pump 20 in position, with no substantial movement relative to the ring 80 under the loads normally applied to the system while the system is in place within the heart. Elongate member 60 preferably has a spherical ball 90 mounted along the length thereof, remote from the distal end 63. Ball 90 desirably is fixedly attached to member 60 as, for example, by welding.
The distal end 63 of member 60 is received in recess 38 of first attachment portion 30 of the pump 20. Preferably, the distal end of member 60 is joined to the attachment portion of the pump by a permanent, fluid-tight connection as, for example, by welding member 60 to the pump shroud. Electrical power wiring 67 extends from the stator 24 of the motor through bore 62 of member 60 and out of the member through a fitting 100 at the proximal end of the member. Preferably, there is a fluid-tight feedthrough (not shown) at fitting 100, at the connection between the distal end 63 and the attachment portion of the pump, or both. The electrical wiring extends out of the fitting 100 to a source of electrical power (not shown) external to the body of the patient or implanted within the body of the patient. Preferably, the power source is a transcutaneous energy transfer or “TET” device. Such a device includes an implantable unit which has a battery and an induction coil. The implantable unit typically is mounted remote from the heart, near the patient's skin. Energy is supplied to the induction coil of the implantable unit by an induction coil incorporated in an external unit worn by the patient. The internal battery provides continued operation during intervals when the patient is not wearing the external unit.
An outflow cannula 40 of extends distally from distal end 27 of pump 20. Outflow cannula 40 is generally in the form of a hollow tube having a proximal end attached to pump 20 and communicating with the outlet 23 (
Preferably, outflow cannula 40 is a single molded polymer piece made of thermoplastic polyurethan (segmented and/or of thermoplastic copolymerized with silicone, polycarbonate-urethanes, polyether-urethanes, aliphatic polycarbonate, or other additives), silicone, polycarbonate-urethanes, polycarbonate, silicone metals and possibly polyether-urethanes, material with or without sulfonated styrenic aliphatic catalyst polymers. Preferably, outflow cannula 40 may be cast with or without titanium wire structures for bend enhancement properties and non-invasive visualization of a catheter typically under x-ray or fluoroscopy. The outflow cannula 40 may contain barium sulfate or other minerals, or metallic marker bands to provide landmark location visualization by fluoroscopic, CAT or other radiological techniques during or after implantation in the patient.
Outflow cannula 40 may be straight or bent and desirably has an appropriate stiffness and hardness to accommodate the native heart and aortic root geometry and also to have non-traumatic contact with tissues. The diameter of the cannula can be tapered from pump body 20 to a smaller diameter near the distal end of the cannula. As further described below, the distal end of the cannula will project through the aortic valve when the apparatus is implanted in a patient. A cannula which tapers in diameter towards its distal end provides relatively low flow resistance due to its large diameter at the proximal end, but also provides a desirable small diameter portion at the aortic valve. The small-diameter portion at the aortic valve helps to minimize aortic valve insufficiency, i.e. retrograde flow through the valve due to poor sealing of the tri-leaflets around the annula. Desirably, the cannula is round in cross-section, at least in the region near tip 70 which will extend through the aortic valve when implanted. A round cross-sectional shape also minimizes aortic valve insufficiency. Merely by way of example, a cannula for carrying about 5 1/min of blood may have a mean interior diameter of about 6 mm.
As best seen in
A family of outflow cannula 40 sizes developed to better accommodate the variety of native heart sizes. It is preferred that he may be patent outflow cannula is preattached to pump 20; however, various cannula sizes may be supplied with the device for attachment in the operating room prior to implantation. The attachment between the outflow cannula and the pump may be of any configuration suitable for maintaining the proximal end in place. The proximal end of the cannula may extend over the distal end of pump housing 22, and may be secured in place by an adhesive bond. Alternatively, a crimp ring may surround the proximal end of the cannula, so that the wall of the cannula is held between the crimp ring and the pump housing.
In this embodiment, the device 10 also includes an anchoring element in the form of a ring 80. Preferably, ring 80 is adapted for mounting adjacent the apex of the patient's heart by sewing around a perimeter of ring 80 to tissue along a wall of the patient's heart. For example, ring 80 may be a metallic structure having a peripheral flange with numerous holes for sewing or stapling the ring to the heart wall. The periphery of ring 80 may be covered with a fabric material such as for example polyester material, expanded polytetrafluoroethylene, felt or the like for promoting tissue growth over the ring to further secure the ring in place. U.S. patent application Ser. No. 11/289,410, entitled “IMPLANT CONNECTOR,” teaches such a ring component and is herein incorporated by reference in its entirety in the present application.
Ring 80 preferably includes a spherical socket 84 adapted to engage the spherical ball 90 of elongate member 60 such that ring 80 is pivotally mounted to elongate member 60 remote from pump 20. In the embodiment depicted, the pivotable connection between the ring and the ball may be a permanent connection formed during manufacture. For example, ball 90 may be entrapped between elements of the ring which are permanently connected to one another during manufacture. Ring 80 is configured to align to the heart wall but can also allow for rotational movement to accommodate the native heart movement.
In a method of implantation according to one embodiment of the invention, the apparatus discussed above, including the ring 80, member 60, pump 20 and outflow cannula 40 is provided as a pre-assembled unit. The surgeon gains access to the heart, preferably using a left subcostal or left thoracotomy incision exposing the left ventricular apex. A pledgeted purse string suture is then applied to the epicardium circumferentially over the pump insertion site. A slit incision or an incision in the form of a cross or X, commonly referred to as a “crux” incision, is made through the apex of the heart into the interior of the left ventricle using a cutting instrument such as a scalpel. Pump 20, member 60 and outflow cannula 40 are then inserted through the crux incision or slit incision and positioned within the left ventricle so that cannula 40 extend through the aortic valve into the aorta. Ring 80 is positioned on the outside of the heart as depicted in
As shown in
The aortic valve is one of the valves of the heart. It lies between the left ventricle and the aorta. The ascending aorta 108 (
When the device is in the implanted condition shown in
In the implanted condition, the axis 19 of the pump extends near the apex of the heart, and the inlet 21 of the pump is aimed generally in the direction toward the apex of the heart. The length of elongate member 60 is such that the inlet 21 of pump 20 is remote from the aortic valve. This position and orientation provide certain advantages. Fibrous structures of the aortic valve, just 30 proximal to the opening of the valve, do not get sucked into the inlet of pump 20. Moreover, the inlet of the pump will not be occluded by the ventricular wall or the interventricular septum of the heart.
The ventricular assist device according to the embodiment discussed above thus provides an intra-ventricular, full output, wearless blood pump that is sized for thoracotomy, sub-costal or other implantation method not requiring a sternotomy. The majority of the device sits within the left ventricle and pumps blood distal to the aortic valve to provide cardiac assistance. The patient population which is typically suited for implantation of this device is similar to the biventricular pacing population; congestive heart failure patients who are failing medical therapy and are willing to undergo a 4 to 6 hour procedure requiring a maximum hospital stay of approximately five days. These patients are very sick and will need 4 to 6 L/min of support initially and may only need 2 to 3 L/min for long term.
Numerous variations and combinations of the features discussed above can be used. For example, device 10 may include dip molded coating of a thin silicone or other polymer around of the exterior of the pump 20, rigid elongate member 60 and ring 80. A dip molded polymer may also be modified by heparin, antithrombotic agents, endothelial tissue growth factors, antibiotics or hydrophilic gels. By extension of the dip molding process as described above the outflow cannula may be formed by the same dip molding process, using a disposable inner core which is removed from the dip-molded cannula before the apparatus is used. Such a process can form the cannula without seams or attachment apparatus as an integral part of the pump housing, and continuous with aforementioned dip coated elements. The anchoring element may be formed or sheathed by dip molded polymer.
In a further variant, the spherical ball 90 used in the arrangement of
The apparatus shown in
In still other configurations, the anchor element may not be a round ring but instead may include one or more feet projecting laterally from the elongated member near the proximal end thereof, the feet being arranged to engage the inside, outside or both of the heart wall adjacent the apex of the heart. Alternatively, the anchor element may be non-circular in cross-section. For example, the anchor element may have other geometric configurations such as triangular, oval, elliptical, or the like.
The elongate member may have various configurations. It should be understood that these alternative configurations are merely exemplary and different configurations may be used without departing from the scope of the present invention. As shown in
In another variant as shown in
As shown in
As shown in
Outflow cannula 40 may be replaced by a graft lumen material fixed to pump 20 as described herein. The graft lumen may be homologous polyester with gel structure, or impregnated with heparin or thromboresistant materials, or augmented with targeted tissue ingrowth promotion factors such as collagen. Similar to the outflow cannula 40, the graft may be tapered, fitted with a polymer tip, fashioned into a terminal tip. The tip of the graft may be arranged to provide hydrodynamic self centering as described above.
In a further embodiment, the outflow cannula 40 discussed above with reference to
In still other embodiments, the outflow cannula may be non-circular and rather take the shape of other geometric configurations such as triangular, oval, elliptical, or the like. As shown in
The triangular cross-section of outflow cannula 140 allows each of three separate outer surfaces of cannula 140 to engage a respective leaf 144 of the tri-leaflet aortic valve. The generally triangular cross-section of cannula 140 is configured to allow for superior engagement of an outer surface of cannula 140 with the leaves 144 of the aortic valve. With the generally triangular cross-sectional shape, each leaflet of the aortic valve can engage a side surface of the cannula which is generally flat or which has a large radius of curvature. This enhances the ability of the valve to seal against the cannula. The fixation of anchor element to the apex of the patient's heart also aids in inhibiting pump 20 from rotating about its own axis 19 and therefore helps to maintain the desired orientation of the outflow cannula 140, with each side surface facing a respective leaf of the aortic valve.
In a further embodiment depicted schematically in FIG. 19, the diffuser blades 128 of the pump, may be connected to a common hub 131 extending along the axis 19 of the pump. The diffuser blades and hub may be fabricated as a separate unit, and this unit may be installed within the tubular housing 122 of the pump distal to the rotor 134.
Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.
This application is a continuation of U.S. patent application Ser. No. 14/867,696, filed Sep. 28, 2015, which application is a continuation of U.S. patent application Ser. No. 14/471,783 filed Aug. 28, 2014, now U.S. Pat. No. 9,173,984, which application is a divisional U.S. patent application Ser. No. 12/322,746 filed Feb. 6, 2009 now U.S. Pat. No. 8,852,072, which is related to and claims priority from Provisional Patent Ser. No. 61/198,682, filed Nov. 7, 2008 and Provisional Patent Ser. No. 61/065,140, filed Feb. 8, 2008 the entirety of all of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
50714 | Jacob | Oct 1865 | A |
2941477 | Dalton | Jun 1960 | A |
3426721 | Justinien | Feb 1969 | A |
3608088 | Dorman et al. | Sep 1971 | A |
3685059 | Bokros et al. | Aug 1972 | A |
4437815 | McMullen | Mar 1984 | A |
4589822 | Clausen et al. | May 1986 | A |
4595390 | Hakim et al. | Jun 1986 | A |
4615691 | Hakim et al. | Oct 1986 | A |
4625712 | Wampler | Dec 1986 | A |
4642036 | Young | Feb 1987 | A |
4817586 | Wampler | Apr 1989 | A |
4846152 | Wampler et al. | Jul 1989 | A |
4906229 | Wampler | Mar 1990 | A |
4908012 | Moise et al. | Mar 1990 | A |
4927407 | Dorman | May 1990 | A |
4994078 | Jarvik | Feb 1991 | A |
5061256 | Wampler | Oct 1991 | A |
5092879 | Jarvik | Mar 1992 | A |
5190528 | Fonger et al. | Mar 1993 | A |
5211546 | Isaacson et al. | May 1993 | A |
5290236 | Mathewson | Mar 1994 | A |
5385581 | Bramm et al. | Jan 1995 | A |
5507629 | Jarvik | Apr 1996 | A |
5527159 | Bozeman, Jr. et al. | Jun 1996 | A |
5588812 | Taylor et al. | Dec 1996 | A |
5613935 | Jarvik | Mar 1997 | A |
5713727 | Veronesi et al. | Feb 1998 | A |
5776190 | Jarvik | Jul 1998 | A |
5824070 | Jarvik | Oct 1998 | A |
5840070 | Wampler | Nov 1998 | A |
5888241 | Jarvik | Mar 1999 | A |
5911685 | Siess et al. | Jun 1999 | A |
5924848 | Izraelev | Jul 1999 | A |
5947892 | Benkowski et al. | Sep 1999 | A |
6015272 | Antaki et al. | Jan 2000 | A |
6058583 | Takeuchi et al. | May 2000 | A |
6100618 | Schoeb et al. | Aug 2000 | A |
6120537 | Wampler | Sep 2000 | A |
6135729 | Aber | Oct 2000 | A |
6155969 | Schima et al. | Dec 2000 | A |
6176822 | Nix et al. | Jan 2001 | B1 |
6227797 | Watterson et al. | May 2001 | B1 |
6227820 | Jarvik | May 2001 | B1 |
6234635 | Seitzinger et al. | May 2001 | B1 |
6234772 | Wampler et al. | May 2001 | B1 |
6234998 | Wampler | May 2001 | B1 |
6244835 | Antaki et al. | Jun 2001 | B1 |
6245007 | Bedingham et al. | Jun 2001 | B1 |
6250880 | Woodard et al. | Jun 2001 | B1 |
6254359 | Aber | Jul 2001 | B1 |
6368083 | Wampler | Apr 2002 | B1 |
6439845 | Veres | Aug 2002 | B1 |
6447265 | Antaki et al. | Sep 2002 | B1 |
6447266 | Antaki et al. | Sep 2002 | B2 |
6527521 | Noda | Mar 2003 | B2 |
6595743 | Kazatchkov et al. | Jul 2003 | B1 |
6641378 | Davis et al. | Nov 2003 | B2 |
6688861 | Wampler | Feb 2004 | B2 |
6716157 | Goldowsky | Apr 2004 | B2 |
6717311 | Locke | Apr 2004 | B2 |
6719791 | Nusser et al. | Apr 2004 | B1 |
6752602 | Schulte Eistrup et al. | Jun 2004 | B2 |
6869567 | Kretchmer | Mar 2005 | B2 |
7667218 | Yamamoto et al. | Feb 2010 | B2 |
20030181928 | Vidlund et al. | Sep 2003 | A1 |
20050250975 | Carrier et al. | Nov 2005 | A1 |
20060122456 | LaRose et al. | Jun 2006 | A1 |
20060161040 | McCarthy et al. | Jul 2006 | A1 |
20060245959 | LaRose et al. | Nov 2006 | A1 |
20060264801 | Bolling et al. | Nov 2006 | A1 |
20070078293 | Shambaugh et al. | Apr 2007 | A1 |
20070100196 | LaRose et al. | May 2007 | A1 |
20070134993 | Tamez et al. | Jun 2007 | A1 |
20070270839 | Jeon et al. | Nov 2007 | A1 |
20090112312 | LaRose et al. | Apr 2009 | A1 |
20100022939 | Schima et al. | Jan 2010 | A1 |
Number | Date | Country |
---|---|---|
0764448 | Mar 1997 | EP |
1067054 | Apr 1967 | GB |
2002-512821 | May 2002 | JP |
9836792 | Aug 1998 | WO |
9853864 | Dec 1998 | WO |
2006067473 | Jun 2006 | WO |
2008106103 | Sep 2008 | WO |
Entry |
---|
Advisory Action dated Apr. 27, 2009 in connection with U.S. Appl. No. 11/003,810, filed Dec. 3, 2004. |
Advisory Action dated Oct. 14, 1 2008 in connection with U.S. Appl. No. 11/243,722, filed Oct. 5, 2005. |
Final Office Action dated Dec. 10, 2008 in connection with U.S. Appl. No. 11/003,8101, filed Dec. 3, 2004. |
Final Office Action dated Jun. 201, 2008 in connection with U.S. Appl. No. 11/243,722, filed Oct. 5, 2005. |
Final Office Action dated Oct. 231, 2008 in connection with U.S. Appl. No. 11/118,551, filed Apr. 29, 2005. |
Final Office Action dated Sep. 30, 2009 in connection !with U.S. Appl. No. 11/243,722, filed Oct. 5, 2005. |
Humphrey, Bruce “Coatings—Using Parylene for Medical Substrate Coating”, www.devicelink.com/ (Jan. 1996) 5 pages. |
International Preliminary Report on Patentability issued by the International Bureau of WIPO dated Apr. 8, 2008 in connection with International Application No. PCT/US2006/21544 dated Dec. 13, 2006. |
International Preliminary Report on Patentability issued by the International Bureau of WIPO dated Mar. 31 2009 in connection with International Application No. PCT/US2005/42495. |
International Search Report issued by the International Searching Authority (ISA/US) in connection with International Application No. PCT/US09/000762 dated Mar. 25, 2009. |
International Search Report issued by the International Searching Authority (ISA/US) in connection with International Application No. PCT/US2005/35964 dated Aug. 20, 2007. |
International Search Report issued by the International Searching Authority (ISA/US) in connection with International Application No. PCT/US2005/42495 dated Apr. 17, 2008. |
International Search Report issued by the International Searching Authority (ISA/US) in connection with International Application No. PCT/US2006/21544 dated Dec. 15, 2006. |
MMPA Standard No. 0100-00; Standard Specifications for Permanent Magnet Materials, Magnet Material Producers Association, 2000. |
Notice of Allowance dated Aug. 281, 2009 in connection with U.S. Appl. No. 11/003,810, filed Dec. 3, 2004. |
Office Action dated Apr. 17, 2009 in connection with U.S. Appl. No. 11/118,551, filed Apr. 29, 2005. |
Office Action dated Dec. 191, 2008 in connection with U.S. Appl. No. 11/243,722, filed Oct. 5, 2005. |
Office Action dated Mar. 17, 2008 in connection with U.S. Appl. No. 11/003,810, filed Dec. 3, 2004. |
Office Action dated Mar. 201, 2008 in connection with U.S. Appl. No. 11/118,551, filed Apr. 29, 2005. |
Office Action dated Sep. 101, 2007 in connection with U.S. Appl. No. 11/243,722, filed Oct. 5, 2005. |
Office Action dated Sep. 22, 2009 in connection with U.S. Appl. No. 11/445,963, filed Jun. 2, 2006. |
Olsen, Don B. “Presidential Address—The History of Continuous-Flow Blood Pumps”, Artificial Organs 24 ( 6), pp. 401-404. |
Siegenthaler et al. “Mechanical Circulatory Assistance for Acute and Chronic Heart Failure: a Review of Current Technology & Clinical Practice”, Journal of Interventional Cardiology, vol. 16/No. 6 (2003) pp. 563-572. |
U.S. Appl. No. 61/135,004, filed Jul. 16, 2008. |
Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/US) in connection with International Application No. PCT/US09/000762 dated Mar. 25, 2009. |
Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/US) in connection with International Application No. PCT/US2005/35964 dated Aug. 20, 2007. |
Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/US) in connection with International Application No. PCT/US2005/42495 dated Apr. 17, 2008. |
Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/US) in connection with International Application No. PCT/US2006/21544 dated Dec. 13, 2006. |
Extended European Search Report dated Aug. 21, 2017, for corresponding European Application No. 09707311.8, consisting of 7 pages. |
Number | Date | Country | |
---|---|---|---|
20170165408 A1 | Jun 2017 | US |
Number | Date | Country | |
---|---|---|---|
61198682 | Nov 2008 | US | |
61065140 | Feb 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12322746 | Feb 2009 | US |
Child | 14471783 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14867696 | Sep 2015 | US |
Child | 15416404 | US | |
Parent | 14471783 | Aug 2014 | US |
Child | 14867696 | US |